Under construction – not a live service
Sign in
Not yet taking people in South KoreaPhase 3

Testing HCP1803-4 for People With Essential Hypertension

Tests how well and how safely HCP1803-4 works in adults with high blood pressure.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Key facts

Where
Goyang-si, South KoreaSee the site
Phase
Phase 3

Where in South Korea

  • Donggguk University Ilsan HospitalGoyang-si, South KoreaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hanmi Pharmaceutical Company Limited
Trial code
NCT07660796
Record updated
30 June 2026
Original description
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential HypertensionRead full original descriptionShow less

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Inclusion: Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions; mean sitSBP < 180 mmHg and mean sitDBP < 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1; 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1; Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg at Visit 2.

Exclusion: Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1; Orthostatic hypotension with symptoms within 3 months prior to visit 1; Severe heart disease or severe neurovascular disease; Moderate or malignant retinopathy; Uncontrolled diabetes mellitus or type I diabetes mellitus; Severe renal diseases; History of malignancy tumor; History of autoimmune disease; History of alcohol or drug abuse; Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1; Secondary hypertensive patient or suspected to be; Clinically significant hematological finding; Active gout or hyperuricemia; Severe or active hepatopathy; Hypokalemia or Hyperkalemia; Hyponatremia or Hypernatremia; Hypercalcemia; Positive to pregnancy test, nursing mother, intention on pregnancy; Considered by investigator as not appropriate to participate in the clinical study with other reason.

ClinicalTrials.gov NCT07660796